Sanofi

5,587.15
+31.90
(0.57%)
ann
There are 2 new updates from the company11 hours ago
Viewcross
right
Market Cap
12,867.55 Cr
EPS
261.78
PE Ratio
35.30
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
10,524.95
52 Week low
4,902.00
PB Ratio
14.87
Debt to Equity
0.02
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy100.00 %
100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,683.45 4,03,916.05 34.10 49,887.20 12.06 9,648 13.77 52.67
5,620.45 1,49,205.29 72.77 8,184.00 0.89 1,600 64.53 45.57
1,461.90 1,18,065.10 23.53 26,520.70 14.17 4,155 47.38 52.92
3,056.05 1,03,430.62 56.27 10,785.70 11.59 1,656 13.54 47.23
1,107.95 92,448.55 17.17 28,905.40 12.36 5,578 1.69 30.37
2,201.15 90,812.16 43.84 10,615.60 19.57 1,942 -16.38 35.15
1,968.45 89,800.21 31.28 20,141.50 19.94 1,936 38.82 43.62
883.10 88,860.52 19.73 19,831.50 13.82 3,831 29.92 40.81
1,094.75 63,583.26 18.24 29,559.20 17.55 3,169 -10.04 43.94
29,597.00 62,891.56 47.49 6,097.20 10.80 1,201 16.01 49.75
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-97.69 %
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Quarterly Financial Results

Quarterly Financials
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
622
572
573
547
579
503
526
529
Expenses
368
393
377
370
400
367
404
397
EBITDA
254
179
195
177
179
137
122
132
Operating Profit %
29 %
24 %
23 %
21 %
22 %
21 %
23 %
23 %
Depreciation
9
9
9
9
9
9
9
10
Interest
0
1
0
0
0
0
0
0
Profit Before Tax
244
169
186
167
169
127
113
122
Tax
54
46
34
30
33
24
30
31
Net Profit
190
123
152
138
137
103
82
91
EPS in ₹
82.78
53.37
65.95
59.79
59.31
44.81
35.69
39.64

Balance Sheet

Balance Sheet
2023
Total Assets
1,715
Fixed Assets
315
Current Assets
1,248
Capital Work in Progress
16
Investments
0
Other Assets
1,384
Total Liabilities
1,715
Current Liabilities
651
Non Current Liabilities
48
Total Equity
1,015
Reserve & Surplus
992
Share Capital
23

Cash Flow

Cash Flow
2023
Net Cash Flow
-610
Investing Activities
38
Operating Activities
230
Financing Activities
-878

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
6.80 %
0.00 %
6.11 %
5.81 %
5.78 %
5.63 %
DIIs
17.16 %
17.39 %
17.65 %
19.03 %
18.65 %
18.60 %
18.27 %
19.21 %
19.47 %
19.66 %
21.69 %
22.47 %
23.08 %
22.79 %
22.82 %
22.93 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
6.97 %
7.09 %
7.21 %
7.01 %
7.65 %
7.92 %
8.81 %
9.13 %
9.29 %
8.89 %
8.60 %
8.09 %
7.97 %
8.31 %
8.21 %
8.33 %
Others
15.48 %
15.12 %
14.74 %
13.56 %
13.30 %
13.09 %
12.53 %
11.26 %
10.85 %
11.05 %
2.51 %
9.04 %
2.44 %
2.69 %
2.79 %
2.70 %
No of Share Holders
0
48,465
53,567
51,646
50,916
59,276
64,542
73,734
76,694
71,513
68,598
62,870
61,849
67,662
66,211
66,401

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 167 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.06 0.00 0.00

Corporate Action

Announcements

Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
11 hours ago
Announcement Under Regulation 30 (LODR)-Newspaper Publication
1 day ago
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
9 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication
Mar 01, 2025, 14:05
Compliances-Reg.24(A)-Annual Secretarial Compliance
Feb 28, 2025, 19:21
Compliances-Reg.24(A)-Annual Secretarial Compliance
Feb 28, 2025, 19:21
Integrated Filing (Financial)
Feb 28, 2025, 16:57
Integrated Filing (Financial)
Feb 28, 2025, 16:57
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 28, 2025, 15:13
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 28, 2025, 15:13
Announcement under Regulation 30 (LODR)-Dividend Updates
Feb 27, 2025, 22:41
Announcement under Regulation 30 (LODR)-Dividend Updates
Feb 27, 2025, 22:41
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 27, 2025, 21:55
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 27, 2025, 21:55
Financial Results For The Financial Year Ended 31St December 2024
Feb 27, 2025, 21:48
Financial Results For The Financial Year Ended 31St December 2024
Feb 27, 2025, 21:48
Board Meeting Outcome for Board Meeting Outcome For Standalone And Consolidated Financial Results For The Quarter And Year Ended 31St December 2024 And Recommendation Of Final Dividend
Feb 27, 2025, 21:24
Board Meeting Outcome for Board Meeting Outcome For Standalone And Consolidated Financial Results For The Quarter And Year Ended 31St December 2024 And Recommendation Of Final Dividend
Feb 27, 2025, 21:24
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 22, 2025, 17:01
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 21, 2025, 15:09
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 19, 2025, 14:55
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 18, 2025, 11:18
Board Meeting Intimation for Consideration And Approval Of The Audited Financial Statements (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St December 2024 And Recommendation O
Feb 13, 2025, 19:04
Appointment of Company Secretary and Compliance Officer
Feb 11, 2025, 15:40
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 05, 2025, 11:37
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Jan 22, 2025, 16:39
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Jan 08, 2025, 18:51
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 06, 2025, 18:29
Change Of Name Of Registrar And Transfer Agent Of The Company
Jan 02, 2025, 16:55
Closure of Trading Window
Dec 27, 2024, 13:33
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dec 09, 2024, 17:52
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Nov 27, 2024, 17:18
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Nov 25, 2024, 17:01
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Nov 13, 2024, 17:19
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Nov 13, 2024, 15:36
Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 08, 2024, 17:45
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Nov 08, 2024, 16:01
Announcement Under Reg. 30
Nov 07, 2024, 18:06
Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended30Th September 2024
Nov 07, 2024, 18:02
Board Meeting Outcome for Board Meeting Outcome For The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 30Th SEPTEMBER 2024
Nov 07, 2024, 17:53
Announcement under Regulation 30 (LODR)-Change in Management
Nov 06, 2024, 17:38
Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Statements (Standalone & Consolidated) For The Quarter And Nine Months Ended 30Th September 2024
Oct 17, 2024, 18:17
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Oct 16, 2024, 16:48
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Oct 11, 2024, 14:24
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Oct 10, 2024, 18:13
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Oct 10, 2024, 12:37
Closure of Trading Window
Sep 26, 2024, 13:23
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Sep 24, 2024, 17:20
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Sep 12, 2024, 18:31
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Sep 04, 2024, 19:20

Technical Indicators

RSI(14)
Neutral
58.74
ATR(14)
Less Volatile
180.21
STOCH(9,6)
Overbought
83.45
STOCH RSI(14)
Overbought
86.38
MACD(12,26)
Bullish
68.06
ADX(14)
Strong Trend
37.77
UO(9)
Bearish
59.33
ROC(12)
Uptrend And Accelerating
9.47
WillR(14)
Neutral
-26.02

About Sanofi

Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products include Lantus (insulin), Combiflam (pain relief), Amaryl (anti-diabetic), Allegra (allergy), Cardace (cardiovascular), and Toujeo (long-acting insulin). Sanofi India is majority-owned by Sanofi and its subsidiary Hoechst GmbH, holding 60.37% of its paid-up share capital. The company has undergone several name changes and acquisitions, including the purchase of Universal Medicare's nutraceutical business in 2011. In 2021, Sanofi India sold its Nutraceuticals business to Universal Nutriscience Private Limited, and in 2022-23, its Consumer Healthcare Business was demerged into a wholly-owned subsidiary.
Chairperson NameAditya Narayan